COMMUNIQUÉS West-GlobeNewswire

Amarin to Report First Quarter 2025 Financial Results and Host Conference Call on May 7, 2025

28/04/2025 - 22:15

DUBLIN and BRIDGEWATER, N.J., April 28, 2025 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced that it will host a conference call with Aaron Berg, President & CEO, and members of Amarin’s [...]

Orchestra BioMed to Participate in Upcoming Institutional Investor Conferences

28/04/2025 - 22:30

NEW HOPE, Pa., April 28, 2025 (GLOBE NEWSWIRE) -- Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO, “Orchestra BioMed” or the “Company”), a biomedical company accelerating high-impact technologies to patients through risk- [...]

Tessera Therapeutics to Present New Data Across Preclinical Programs for its Gene Writing™ and Delivery Platforms at the American Society of Gene and Cell Therapy 28th Annual Meeting

28/04/2025 - 22:30

SOMERVILLE, Mass., April 28, 2025 (GLOBE NEWSWIRE) -- Tessera Therapeutics, the biotechnology company pioneering a new approach in genetic medicine known as Gene Writing™, today announced seven presentations of new [...]

Voyager Next-Generation CNS Capsids Featured at ASGCT 28th Annual Meeting

28/04/2025 - 22:30

- Oral presentation on tau silencing gene therapy VY1706, which has previously shown up to 73% knockdown of tau mRNA in NHPs in the CNS following a single IV dose of 1.3e13 vg/kg - - Featured data also include anti- [...]

ORIC® Pharmaceuticals Presents Preclinical Data to Support the Potential of ORIC-944 as a Best-in-Class PRC2 Inhibitor for the Treatment of Prostate Cancer at the 2025 American Association for Cancer Research (AACR) Annual Meeting

28/04/2025 - 22:30

SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, April 28, 2025 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of [...]

Cellectis Presents Non-Viral Gene Editing and Base Editing Innovation at the ASGCT Annual Meeting

28/04/2025 - 22:30

NEW YORK, April 28, 2025 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving [...]

iTeos Reports First Quarter 2025 Financial Results and Provides Business Updates

28/04/2025 - 22:30

- Topline interim dataset from GALAXIES Lung-201 with >240 patients anticipated in 2Q25 - Interim datasets from GALAXIES H&N-202 and TIG-006 HNSCC with ~200 patients anticipated in 2025 - Cash balance and [...]

CAMP4 to Present New Preclinical Data from its Urea Cycle Disorders and SYNGAP1-Related Disorders Programs at the 28th American Society of Gene and Cell Therapy Annual Meeting

28/04/2025 - 22:30

Preclinical data to showcase the potential of regRNA-targeting to increase protein levels in a clinically meaningful way by upregulating gene expression Interim safety data including patient demographic data from all [...]

Century Therapeutics Announces Two Upcoming Presentations at the ASGCT 28th Annual Meeting

28/04/2025 - 22:30

PHILADELPHIA, April 28, 2025 (GLOBE NEWSWIRE) -- Century Therapeutics, Inc. (‘Century’, NASDAQ: IPSC), an innovative biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies in [...]

Axovia Therapeutics Announces Three Upcoming Poster Presentations at ASGCT

28/04/2025 - 22:30

LONDON, April 28, 2025 (GLOBE NEWSWIRE) -- Axovia Therapeutics Ltd., a biotechnology company developing therapies to address the genetic causes of blindness and obesity, today announced that Co-Founder and Chief [...]

Fractyl Health to Present Compelling Preclinical Data from its Rejuva® Single-Administration Smart GLP-1 Pancreatic Gene Therapy Platform at the American Society of Gene and Cell Therapy (ASGCT) 2025 Annual Meeting

28/04/2025 - 22:30

BURLINGTON, Mass., April 28, 2025 (GLOBE NEWSWIRE) -- Fractyl Health, Inc. (Nasdaq: GUTS) (“the Company”), a metabolic therapeutics company focused on pattern-breaking approaches to treat the root causes of obesity and [...]

Shape Therapeutics Announces Multiple Oral and Poster Presentations at the American Society of Gene & Cell Therapy 28th Annual Meeting

28/04/2025 - 22:30

Data support potential of innovative gene therapy using novel RNA editing, paired with targeted AAV.ai delivery and scalable manufacturing platforms SEATTLE, April 28, 2025 (GLOBE NEWSWIRE) -- Shape Therapeutics, a [...]

Spur Therapeutics Announces Oral and Poster Presentations Highlighting Data from Clinical and Preclinical Programs at Upcoming ASGCT Annual Meeting

28/04/2025 - 22:30

LONDON, April 28, 2025 (GLOBE NEWSWIRE) -- Spur Therapeutics today announced that it will share new data from its gene therapy programs in Gaucher disease, GBA1 Parkinson’s disease and adrenomyeloneuropathy in oral and [...]

Edesa Biotech to Participate in Bloom Burton Healthcare Investor Conference

28/04/2025 - 22:30

TORONTO, April 28, 2025 (GLOBE NEWSWIRE) -- Edesa Biotech, Inc. (Nasdaq:EDSA), a clinical-stage biopharmaceutical company focused on developing host-directed therapeutics for immuno-inflammatory diseases, announced [...]

Editas Medicine to Present Preclinical Data Demonstrating Progress in the Development of an in vivo Gene Editing Pipeline at the American Society of Gene and Cell Therapy Annual Meeting

28/04/2025 - 22:31

CAMBRIDGE, Mass., April 28, 2025 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a pioneering gene editing company, today announced that five abstracts have been accepted for presentation, including one oral [...]

Arbor Biotechnologies to Present Foundational Data for PH1 and CNS Programs at the American Society of Gene and Cell Therapy (ASGCT) 28th Annual Meeting

28/04/2025 - 22:35

- Oral presentation to include preclinical data supporting the clinical advancement of ABO-101 for the treatment of primary hyperoxaluria type 1 - Four poster presentations collectively demonstrate advancement of [...]

Artiva Biotherapeutics to Present Longer-term Phase 1/2 Data for AlloNK® in Combination with Rituximab in Patients with B-cell-Non-Hodgkin Lymphoma at the ASGCT 28th Annual Meeting

28/04/2025 - 22:35

Prolonged duration of response, deep B-cell depletion, and well-tolerated safety profile support the potential of AlloNK ® + rituximab for the treatment of B-cell driven diseases in a community setting Additional poster [...]

Tevogen Reaffirms Oncology Top-Line Revenue Forecast of $1 Billion in Launch Year and Cumulative 5-Year Estimate Between $10 Billion and $14 Billion

28/04/2025 - 22:36

Reflects business philosophy of commercial success through patient accessibility Recently executed agreement with CD 8 Technology Services LLC providing up to $50 million for Company’s dedicated R&D and [...]

Cellectis présente une approche non virale d’édition du génome et des innovations avec les base editors à l’ASGCT 2025

28/04/2025 - 22:39

NEW YORK, 28 avr. 2025 (GLOBE NEWSWIRE) -- Cellectis (Euronext Growth : ALCLS - NASDAQ : CLLS) (la "Société"), société de biotechnologie de stade clinique, qui utilise sa technologie pionnière d'édition de génome pour [...]